You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-EGFR-Tucatinib
Tucatinib

Chemical Structure : Tucatinib

CAS No.: 937263-43-9

Tucatinib (Irbinitinib, ONT-380, ARRY-380)

Catalog No.: PC-38023Not For Human Use, Lab Use Only.

Tucatinib (Irbinitinib, ONT-380, ARRY-380) is a potent, selective, reversible and ATP-competitive inhibitor of ErbB-2 (HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively.

Packing Price Stock Quantity
25 mg $218 In stock
50 mg $398 In stock
100 mg $698 In stock
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Tucatinib (Irbinitinib, ONT-380, ARRY-380) is a potent, selective, reversible and ATP-competitive inhibitor of ErbB-2 (HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively.
Tucatinib displays 500-fold selective for HER2 versus EGFR in cell-based assays.
Tucatinib inhibits the phosphorylation of HER2 in a L755S mutant MCF-10A cell line and inhibits the growth of 3 L755S mutant tumor models derived from colorectal, gastric and non-small cell lung cancer.
Tucatinib also potently inhibits the phosphorylation of HER2 in a V777L mutant MCF-10A cell line, and in a colorectal PDX model containing a V777L mutation, tucatinib alone or in combination with trastuzumab induces tumor regressions.
Tucatinib inhibits HER2 phosphorylation, but not EGFR phosphorylation, and inhibits the phosphorylation of HER2, HER3, Erk1/2, MEK1 and AKT in the G776V_G/C HER2 mutant NCI-H1781 cell line.

Physicochemical Properties

M.Wt 480.53
Formula C26H24N8O2
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine

References

1. Moulder SL, et al. Clin Cancer Res. 2017 Jul 15;23(14):3529-3536.

2. Murthy RK, et al. N Engl J Med. 2020 Feb 13;382(7):597-609.

3. Kulukian A, et al. Mol Cancer Ther. 2020 Apr;19(4):976-987.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: